FDAnews
www.fdanews.com/articles/130777-fda-extends-salix-pharma-8217-s-pdufa-goal-date-for-xifaxan

FDA Extends Salix Pharma’s PDUFA Goal Date for Xifaxan

October 4, 2010
Salix Pharmaceuticals, Ltd. announced Monday that the U.S. FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for the Agency’s Priority Review of the efficacy supplement to NDA 21-361 for XIFAXAN (rifaximin) 550 mg Tablets by three months.
StreetInsider